Screening for Heart Disease in Kidney Transplant Candidates
This study, called CARSK, is looking at how we screen for heart disease (coronary artery disease or CAD) in people waiting for a kidney transplant. Currently, people are screened every 1-2 years. This study wants to see if stopping this regular screening after you're on the waitlist is just as safe as continuing it. The study will compare two groups: one that continues regular screening and one that doesn't have further screening after joining the waitlist. The main goal is to see if one approach leads to fewer serious heart problems (Major Adverse Cardiac Events or MACE). You might be able to join if you are an adult, have kidney failure requiring dialysis, are being assessed for or are on the kidney transplant waiting list, and are expected to need CAD screening before transplant. The study aims to enroll 3306 participants, but its current recruitment status is unclear.
- Study design
- This is an interventional study comparing two groups: one with regular screening for heart disease and one with no further screening. It plans to include 3306 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 60 months, with a maximum follow-up of 72 months, including 12 months after transplant.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates
At a glance
Conditions
Where it's being run
22 sites across 10 statesStudy leadership
- Jagbir Gill, MD · PRINCIPAL_INVESTIGATOR · University of British Columbia
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- MACEThe investigators will analyse time to first MACE event for the duration of the trial (60 months), depending on patient's date of transplant. Follow-up will be 12 months posttransplant. Maximum follow-up is 72 months.
Primary efficacy: major adverse cardiac event (MACE), defined as any of the following: cardiovascular death, myocardial infarction, emergency revascularisation, hospitalisation with unstable angina. The outcome will be assessed by: 1. Notification to the transplant coordinators when patients are admitted in hospital (this is the usual standard of care in waitlisted patients). 2. The trial coordinator will gather electronic medical records, letters, procedure notes, and will fill in the relevant case record form on the REDCap database (managed by Sydney local health district). All data are encrypted and stored on servers at SLHD, where it is backed up. 3. Patients will be followed up 6-monthly (alternating by phone and clinic visits) where trial coordinators will discuss any hospitalisation with the patients.